Is MCRB or NBP more profitable?

I-Mab's return on equity of 0.00% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics N/A -130.29% -35.35% I-Mab N/A N/A N/A

Is MCRB or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics N/A -130.29% -35.35% Minerva Neurosciences N/A N/A -32.63%

Seres Therapeutics (MCRB) Competitors

$4.97 -0.26 (-4.97%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$4.94 -0.03 (-0.60%)

As of 07/24/2026 07:34 PM Eastern

Compare

MCRB vs. NBP, DTIL, RNA, NERV, and TNXP

Should you buy Seres Therapeutics stock or one of its competitors? MarketBeat compares Seres Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Seres Therapeutics include I-Mab (NBP), Precision BioSciences (DTIL), Avidity Biosciences (RNA), Minerva Neurosciences (NERV), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry.

How does Seres Therapeutics compare to I-Mab?

Seres Therapeutics (NASDAQ:MCRB) and I-Mab (NASDAQ:NBP) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Seres Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 242.05%. I-Mab has a consensus target price of $9.00, suggesting a potential upside of 408.47%. Given I-Mab's higher probable upside, analysts plainly believe I-Mab is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

I-Mab's return on equity of 0.00% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
I-Mab	N/A	N/A	N/A

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by insiders. Comparatively, 22.1% of I-Mab shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Seres Therapeutics has higher revenue and earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	60.90	$5.70M	-$5.17	N/A
I-Mab	N/A	N/A	-$46.27M	-$0.36	N/A

Seres Therapeutics has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

In the previous week, I-Mab had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 4 mentions for I-Mab and 2 mentions for Seres Therapeutics. I-Mab's average media sentiment score of 0.69 beat Seres Therapeutics' score of 0.43 indicating that I-Mab is being referred to more favorably in the news media.

Company	Overall Sentiment
Seres Therapeutics	Neutral
I-Mab	Positive

Summary

I-Mab beats Seres Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Seres Therapeutics compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Seres Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -85.37% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Seres Therapeutics	N/A	-130.29%	-35.35%

In the previous week, Precision BioSciences and Precision BioSciences both had 2 articles in the media. Precision BioSciences' average media sentiment score of 1.88 beat Seres Therapeutics' score of 0.43 indicating that Precision BioSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Precision BioSciences	Very Positive
Seres Therapeutics	Neutral

Seres Therapeutics has lower revenue, but higher earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$45.07M	4.17	-$45.72M	-$3.67	N/A
Seres Therapeutics	$790K	60.90	$5.70M	-$5.17	N/A

Precision BioSciences has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Precision BioSciences currently has a consensus price target of $32.25, indicating a potential upside of 342.39%. Seres Therapeutics has a consensus price target of $17.00, indicating a potential upside of 242.05%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts clearly believe Precision BioSciences is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Precision BioSciences beats Seres Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Seres Therapeutics compare to Avidity Biosciences?

Seres Therapeutics (NASDAQ:MCRB) and Avidity Biosciences (NASDAQ:RNA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Seres Therapeutics has higher earnings, but lower revenue than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	60.90	$5.70M	-$5.17	N/A
Avidity Biosciences	$36.68M	5.36	-$322.30M	-$0.97	N/A

Seres Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 242.05%. Avidity Biosciences has a consensus price target of $67.60, indicating a potential upside of 488.34%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.28

Seres Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%

Seres Therapeutics has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Avidity Biosciences has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

59.3% of Seres Therapeutics shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Avidity Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Avidity Biosciences had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 3 mentions for Avidity Biosciences and 2 mentions for Seres Therapeutics. Avidity Biosciences' average media sentiment score of 0.62 beat Seres Therapeutics' score of 0.43 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Seres Therapeutics	Neutral
Avidity Biosciences	Positive

Summary

Avidity Biosciences beats Seres Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Seres Therapeutics compare to Minerva Neurosciences?

Seres Therapeutics (NASDAQ:MCRB) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Seres Therapeutics had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 2 mentions for Seres Therapeutics and 1 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.87 beat Seres Therapeutics' score of 0.43 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Seres Therapeutics	Neutral
Minerva Neurosciences	Very Positive

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Seres Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 242.05%. Minerva Neurosciences has a consensus target price of $10.50, indicating a potential upside of 159.90%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Seres Therapeutics is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Minerva Neurosciences' return on equity of 0.00% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Minerva Neurosciences	N/A	N/A	-32.63%

Seres Therapeutics has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.16, suggesting that its share price is 116% less volatile than the broader market.

Seres Therapeutics has higher revenue and earnings than Minerva Neurosciences. Seres Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	60.90	$5.70M	-$5.17	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

Summary

Seres Therapeutics beats Minerva Neurosciences on 10 of the 14 factors compared between the two stocks.

How does Seres Therapeutics compare to Tonix Pharmaceuticals?

Seres Therapeutics (NASDAQ:MCRB) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Seres Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Tonix Pharmaceuticals' return on equity of -67.65% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Seres Therapeutics has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

Seres Therapeutics has higher earnings, but lower revenue than Tonix Pharmaceuticals. Seres Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	60.90	$5.70M	-$5.17	N/A
Tonix Pharmaceuticals	$13.11M	12.01	-$124.02M	-$14.36	N/A

In the previous week, Seres Therapeutics and Seres Therapeutics both had 2 articles in the media. Tonix Pharmaceuticals' average media sentiment score of 0.94 beat Seres Therapeutics' score of 0.43 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Seres Therapeutics	Neutral
Tonix Pharmaceuticals	Positive

Seres Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 242.05%. Tonix Pharmaceuticals has a consensus target price of $24.00, suggesting a potential upside of 142.91%. Given Seres Therapeutics' higher probable upside, equities research analysts plainly believe Seres Therapeutics is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Seres Therapeutics and Tonix Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Seres Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MCRB vs. The Competition

Export

Metric	Seres Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$50.65M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.96	21.48	27.14	23.64
Price / Sales	60.90	169.92	517.01	89.03
Price / Cash	4.81	157.90	50.54	59.64
Price / Book	1.02	7.88	10.28	6.07
Net Income	$5.70M	$23.86M	$3.60B	$331.99M
7 Day Performance	-6.75%	-3.82%	-1.27%	-0.63%
1 Month Performance	-27.34%	-2.61%	-0.37%	-2.00%
1 Year Performance	-65.79%	32.79%	18.30%	13.62%

Seres Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MCRB Seres Therapeutics	2.4834 of 5 stars	$4.97 -5.0%	$17.00 +242.1%	-62.9%	$50.65M	$790K	N/A	330	Short Interest Increase
NBP I-Mab	2.4367 of 5 stars	$1.79 +0.6%	$9.00 +402.8%	N/A	$205.85M	$3.89M	N/A	380	News Coverage
DTIL Precision BioSciences	2.7118 of 5 stars	$7.36 -6.5%	$32.25 +338.2%	+45.8%	$203.06M	$34.26M	N/A	200	News Coverage Positive News
RNA Avidity Biosciences	2.3711 of 5 stars	$11.76 -3.2%	$67.60 +474.8%	-65.4%	$201.17M	$36.68M	N/A	190
NERV Minerva Neurosciences	1.7348 of 5 stars	$4.37 +2.3%	$10.50 +140.3%	+86.2%	$198.93M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MCRB) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seres Therapeutics (MCRB) Competitors

MCRB vs. NBP, DTIL, RNA, NERV, and TNXP

How does Seres Therapeutics compare to I-Mab?

Summary

How does Seres Therapeutics compare to Precision BioSciences?

Summary

How does Seres Therapeutics compare to Avidity Biosciences?

Summary

How does Seres Therapeutics compare to Minerva Neurosciences?

Summary

How does Seres Therapeutics compare to Tonix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Seres Therapeutics (MCRB) Competitors

MCRB vs. NBP, DTIL, RNA, NERV, and TNXP

How does Seres Therapeutics compare to I-Mab?

Do analysts rate MCRB or NBP?

Is MCRB or NBP more profitable?

Do insiders and institutionals hold more shares of MCRB or NBP?

Which has stronger earnings and valuation, MCRB or NBP?

Which has more volatility and risk, MCRB or NBP?

Does the media favor MCRB or NBP?

Summary

How does Seres Therapeutics compare to Precision BioSciences?

Do institutionals and insiders believe in DTIL or MCRB?

Is DTIL or MCRB more profitable?

Does the media prefer DTIL or MCRB?

Which has better earnings & valuation, DTIL or MCRB?

Which has more volatility and risk, DTIL or MCRB?

Do analysts prefer DTIL or MCRB?

Summary

How does Seres Therapeutics compare to Avidity Biosciences?

Which has better valuation and earnings, MCRB or RNA?

Do analysts prefer MCRB or RNA?

Is MCRB or RNA more profitable?

Which has more risk and volatility, MCRB or RNA?

Do institutionals & insiders have more ownership in MCRB or RNA?

Does the media favor MCRB or RNA?

Summary

How does Seres Therapeutics compare to Minerva Neurosciences?

Does the media favor MCRB or NERV?

Do insiders & institutionals believe in MCRB or NERV?

Do analysts recommend MCRB or NERV?

Is MCRB or NERV more profitable?

Which has more risk & volatility, MCRB or NERV?

Which has preferable earnings and valuation, MCRB or NERV?

Summary

How does Seres Therapeutics compare to Tonix Pharmaceuticals?

Is MCRB or TNXP more profitable?

Do insiders and institutionals have more ownership in MCRB or TNXP?

Which has more risk and volatility, MCRB or TNXP?

Which has better valuation & earnings, MCRB or TNXP?

Does the media favor MCRB or TNXP?

Do analysts prefer MCRB or TNXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools